Literature DB >> 2550167

Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity.

R A Reeves1, W H Boer, L DeLeve, F H Leenen.   

Abstract

We determined whether the beta-blockade disappearance rate would determine the degree of subsequent transient beta-adrenoceptor hyperresponsiveness after abrupt withdrawal of a beta-adrenoceptor drug. In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day. beta-Receptor responsiveness was assessed before and repeatedly after abrupt drug withdrawal by infusion of isoproterenol and epinephrine and by ergometer exercise. In the 13 days after drug discontinuation, peak beta-receptor sensitivity correlated (p less than 0.05) with the disappearance rate of beta-blockade as assessed by heart rate responses to isoproterenol (r = 0.68) and to submaximal exercise (r = 0.62) and by diastolic blood pressure responses to isoproterenol (r = 0.86) and epinephrine (r = 0.86). Plasma catecholamine levels and renin activity showed no overshoot. beta-Blockers with long plasma t1/2 values may prevent beta-blocker withdrawal syndromes by means of "self-tapering."

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550167     DOI: 10.1038/clpt.1989.139

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?

Authors:  F H Leenen
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study.

Authors:  Donald Redelmeier; Damon Scales; Alexander Kopp
Journal:  BMJ       Date:  2005-10-06

3.  Persistence of anti-hypertensive effect after missed dose of perindopril.

Authors:  K W Tan; F H Leenen
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.